Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Hemostatic Disorders

ClinicalTrials.gov lists 4,630 trials for Hemostatic Disorders or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 180.

MeSH D020141 Cardiovascular Diseases C14 C15
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 963 Phase 1/2 Phase 1/2 514 Phase 2 Phase 2 1,300 Phase 2/3 Phase 2/3 42 Phase 3 Phase 3 410 Phase 4 Phase 4 95 Not applicable Not applicable 468 Observational Observational 803 Phase 1 Phase 1 963 Phase 1/2 Phase 1/2 514 Phase 2 Phase 2 1,300 Phase 2/3 Phase 2/3 42 Phase 3 Phase 3 410 Phase 4 Phase 4 95 Not applicable Not applicable 468 Observational Observational 803

Trials per phase (log scale)

2 more sections with rows

358 of the 4,630 trials are tagged with Hemostatic Disorders itself; the rest are tagged with a narrower condition beneath it.

Get the Hemostatic Disorders report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Hemostatic Disorders trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 16 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 244

1990: 1 trials (Phase 2 1) 1991: 1 trials (Phase 2 1) 1992: 4 trials (Phase 2 2, Phase 1/2 1, Phase 1 1) 1993: 6 trials (Observational 2, Phase 3 1, Phase 2 3) 1994: 6 trials (Phase 3 3, Phase 2 3) 1995: 12 trials (Observational 1, Phase 3 4, Phase 2 5, Phase 1/2 1, Phase 1 1) 1996: 17 trials (Observational 2, Phase 3 5, Phase 2 8, Phase 1 2) 1997: 29 trials (Observational 1, Not applicable 3, Phase 3 5, Phase 2 13, Phase 1/2 2, Phase 1 5) 1998: 54 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 3 6, Phase 2/3 1, Phase 2 32, Phase 1/2 2, Phase 1 9) 1999: 52 trials (Not applicable 4, Phase 3 8, Phase 2 24, Phase 1/2 5, Phase 1 11) 2000: 64 trials (Observational 4, Not applicable 6, Phase 4 1, Phase 3 14, Phase 2/3 1, Phase 2 24, Phase 1/2 9, Phase 1 5) 2001: 53 trials (Observational 3, Not applicable 7, Phase 4 1, Phase 3 5, Phase 2/3 2, Phase 2 21, Phase 1/2 6, Phase 1 8) 2002: 74 trials (Observational 7, Not applicable 6, Phase 3 11, Phase 2/3 1, Phase 2 30, Phase 1/2 8, Phase 1 11) 2003: 79 trials (Observational 5, Not applicable 10, Phase 4 2, Phase 3 16, Phase 2/3 1, Phase 2 18, Phase 1/2 10, Phase 1 17) 2004: 102 trials (Observational 6, Not applicable 7, Phase 4 3, Phase 3 9, Phase 2/3 2, Phase 2 44, Phase 1/2 13, Phase 1 18) 2005: 120 trials (Observational 8, Not applicable 8, Phase 4 1, Phase 3 13, Phase 2 50, Phase 1/2 16, Phase 1 24) 2006: 133 trials (Observational 15, Not applicable 6, Phase 4 3, Phase 3 23, Phase 2 48, Phase 1/2 16, Phase 1 22) 2007: 136 trials (Other 1, Observational 11, Not applicable 9, Phase 4 2, Phase 3 13, Phase 2/3 1, Phase 2 50, Phase 1/2 17, Phase 1 32) 2008: 167 trials (Observational 27, Not applicable 7, Phase 4 1, Phase 3 17, Phase 2/3 2, Phase 2 55, Phase 1/2 15, Phase 1 43) 2009: 137 trials (Other 2, Observational 17, Not applicable 7, Phase 4 2, Phase 3 19, Phase 2/3 4, Phase 2 41, Phase 1/2 20, Phase 1 25) 2010: 169 trials (Observational 29, Not applicable 13, Phase 4 5, Phase 3 12, Phase 2 54, Phase 1/2 26, Phase 1 30) 2011: 147 trials (Observational 23, Not applicable 12, Phase 4 3, Phase 3 13, Phase 2/3 1, Phase 2 45, Phase 1/2 23, Phase 1 27) 2012: 153 trials (Observational 16, Not applicable 8, Phase 4 2, Phase 3 11, Phase 2 58, Phase 1/2 20, Phase 1 38) 2013: 140 trials (Observational 21, Not applicable 14, Phase 4 1, Phase 3 13, Phase 2/3 2, Phase 2 39, Phase 1/2 22, Phase 1 28) 2014: 165 trials (Observational 23, Not applicable 11, Phase 4 5, Phase 3 10, Phase 2/3 2, Phase 2 44, Phase 1/2 22, Phase 1 48) 2015: 172 trials (Observational 34, Not applicable 12, Phase 4 3, Phase 3 12, Phase 2/3 1, Phase 2 59, Phase 1/2 15, Phase 1 36) 2016: 172 trials (Observational 35, Not applicable 16, Phase 4 5, Phase 3 10, Phase 2/3 1, Phase 2 59, Phase 1/2 18, Phase 1 28) 2017: 193 trials (Observational 43, Not applicable 11, Phase 4 5, Phase 3 17, Phase 2/3 1, Phase 2 50, Phase 1/2 23, Phase 1 43) 2018: 201 trials (Observational 50, Not applicable 18, Phase 4 2, Phase 3 10, Phase 2/3 4, Phase 2 61, Phase 1/2 18, Phase 1 38) 2019: 215 trials (Observational 42, Not applicable 21, Phase 4 7, Phase 3 15, Phase 2/3 1, Phase 2 49, Phase 1/2 30, Phase 1 50) 2020: 213 trials (Observational 60, Not applicable 33, Phase 4 3, Phase 3 19, Phase 2/3 2, Phase 2 39, Phase 1/2 12, Phase 1 45) 2021: 244 trials (Observational 52, Not applicable 27, Phase 4 4, Phase 3 12, Phase 2/3 1, Phase 2 60, Phase 1/2 25, Phase 1 63) 2022: 244 trials (Observational 61, Not applicable 33, Phase 4 11, Phase 3 17, Phase 2 46, Phase 1/2 24, Phase 1 52) 2023: 239 trials (Observational 61, Not applicable 43, Phase 4 3, Phase 3 13, Phase 2/3 3, Phase 2 41, Phase 1/2 33, Phase 1 42) 2024: 213 trials (Observational 53, Not applicable 35, Phase 4 5, Phase 3 15, Phase 2 33, Phase 1/2 18, Phase 1 54) 2025: 212 trials (Observational 47, Not applicable 41, Phase 4 7, Phase 3 13, Phase 2/3 2, Phase 2 42, Phase 1/2 16, Phase 1 44)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 221
2025 212
2024 213
2023 239
2022 244
2021 244
2020 213
2019 215
2018 201
2017 193

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 240 trials starting in 2026 and about 230 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 542 trials still running at the 2026-10-09 snapshot; registered median of 38 months across 2,864 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Hemostatic Disorders trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 963
Phase 1/2 514
Phase 2 1,300
Phase 2/3 42
Phase 3 410
Phase 4 95
Not applicable 468
Observational 803
Expanded access 34
Unknown 1

How many Hemostatic Disorders trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 175
Recruiting 636
Enrolling by invitation 15
Active, not recruiting 338
Available 6

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Hemostatic Disorders trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 180
Celgene 93
Janssen Research & Development, LLC 66
Amgen 44
GlaxoSmithKline 42

Which drugs are being tested for Hemostatic Disorders? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 333
Melphalan 228
POMALIDOMIDE 185
RITUXIMAB 114
THALIDOMIDE 106

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Dexamethasone/Dexamethasone acetate 720
Bortezomib SC 412
X: Lenalidomide 393
SQ Fludarabine 214
Daratumumab SC 198

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Hemostatic Disorders trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 4,691 323
Pyrexia 1,614 222
Thrombocytopenia 1,398 183
Sepsis 1,284 305
Febrile neutropenia 1,275 238

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Hemostatic Disorders? (6)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Clinical screening for menorrhagia and other bleeding symptoms in Nigerian women. Annals of African medicine 2021 Yes
Fetal vascular malperfusion, an update. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2018 Yes
Preoperative hemostatic assessment: a new and simple bleeding questionnaire. Canadian journal of anaesthesia = Journal canadien d'anesthesie 2016 Yes
Pre-interventional haemostatic assessment: Guidelines from the French Society of Anaesthesia and Intensive Care. European journal of anaesthesiology 2013 Yes
Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction? Journal of hepatology 2011 Yes

Showing 5 of 6 publications.

Start your 14-day trial Email me all 6 publications as a PDF

Sub-conditions in MeSH (9)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages